As the COVID-19 treatment Hydroxychloroquine continues to be portrayed by mainstream media as an unsuccessful, dangerous drug, Vladimir Zelenko, MD has been saving his patients lives with his “Zelenko Protocol” since March.
In his first interview since his HCQ study was officially released, Zelenko talks about how he developed his protocol, the attack against the drug, and how his letter to the President might have changed history.
Hydroxychloroquine coverage begins at 38:30; Zelenko interview begins at 41:41
COVID CRIMES AGAINST HUMANITY? John Ziegler Goes Viral Over Lockdown; CA Mayor Defies Newsom Mask Order; Dr. Zelenko’s HCQ Protocol Saving Lives; Kids & Masks: Are They Safe?; ICAN Sues NIH…Again! #CovidCrimes #Heatlh #Ziegler #ZelenkoProtocol https://t.co/8KzbKbXZih
— The HighWire (@HighWireTalk) July 2, 2020
The study using my data is finally available to read online.
Key takeaways: Identify high risk patients. Treat early. Zinc + low dose Hydroxychloroquine + Azithromycin.
I saw 5x less death when patients were prescribed these drugs.https://t.co/JnsVm1Vtw6#ZelenkoProtocol
— Dr. Zev Zelenko (@zev_dr) July 3, 2020
Dr. Zelenko talks about how he developed his #HCQ protocol, the attack against the drug, and how his letter to the President might have changed history.#ZelenkoProtocol #BeBrave #SaveLives #Covid19 https://t.co/ShGv88oTQo
— The HighWire (@HighWireTalk) July 3, 2020
Source: Mordechai Sones – Arutz Sheva
COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study
Martin Scholz, Roland Derwand, Vladimir Zelenko
Version 1 : Received: 30 June 2020 / Approved: 3 July 2020 / Online: 3 July 2020 (08:52:22 CEST)
How to cite: Scholz, M.; Derwand, R.; Zelenko, V. COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study. Preprints 2020, 2020070025 (doi: 10.20944/preprints202007.0025.v1).
Abstract
Objective: To describe outcomes of patients with coronavirus disease 2019 (COVID-19) in the outpatient setting after early treatment with zinc, low dose hydroxychloroquine, and azithromycin (the triple therapy) dependent on risk stratification. Design: Retrospective case series study. Setting: General practice. Participants: 141 COVID-19 patients with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in the year 2020. Main Outcome Measures: Risk-stratified treatment decision, rate of hospitalization and all-cause death. Results: Of 335 positively PCR-tested COVID-19 patients, 127 were treated with the triple therapy. 104 of 127 met the defined risk stratification criteria and were included in the analysis. In addition, 37 treated and eligible patients who were confirmed by IgG tests were included in the treatment group (total N=141). 208 of the 335 patients did not meet the risk stratification criteria and were not treated. After 4 days (median, IQR 3-6, available for N=66/141) of onset of symptoms, 141 patients (median age 58 years, IQR 40-60; 73% male) got a prescription for the triple therapy for 5 days. Independent public reference data from 377 confirmed COVID-19 patients of the same community were used as untreated control. 4 of 141 treated patients (2.8%) were hospitalized, which was significantly less (p<0.001) compared with 58 of 377 untreated patients (15.4%) (odds ratio 0.16, 95% CI 0.06-0.5). Therefore, the odds of hospitalization of treated patients were 84% less than in the untreated group. One patient (0.7%) died in the treatment group versus 13 patients (3.5%) in the untreated group (odds ratio 0.2, 95% CI 0.03-1.5; p=0.16). There were no cardiac side effects. Conclusions: Risk stratification-based treatment of COVID-19 outpatients as early as possible after symptom onset with the used triple therapy, including the combination of zinc with low dose hydroxychloroquine, was associated with significantly less hospitalizations and 5 times less all-cause deaths.
Subject Areas
SARS-CoV-2; COVID-19; outpatients; treatment; zinc; hydroxychloroquine; azithromycin
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original: Preprints